For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenues | - | 0 | ||
| Research and development | - | 423,277 | ||
| General and administrative | 527,902 | 919,488 | ||
| Asset impairment loss | - | 402,746 | ||
| Total operating expenses | 527,902 | 1,745,511 | ||
| Loss from operations | -527,902 | -1,745,511 | ||
| Interest income (expense) | 8,116 | 4,866 | ||
| Inducement expense | - | 0 | ||
| Change in fair value of contingent consideration and derivative financial instruments | 47,280 | 698,073 | ||
| Loss before income taxes | -472,506 | -1,042,572 | ||
| Income tax benefit | - | 0 | ||
| Net loss | -472,506 | -1,042,572 | ||
| Basic | -0.04 | -0.09 | ||
| Basic | 11,620,317 | 11,328,122 | ||
| Diluted | -0.04 | -0.09 | ||
| Diluted | 11,620,317 | 11,328,122 | ||
Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc. (HEPA)